INDIA – Drug major Lupin has announced the launch of its digital asthma educator platform to guide patients on the correct technique of using inhalers. The new platform is the latest initiative under Lupin’s long-running umbrella program, “Joint Airways Initiative” (JAI), for patients suffering from respiratory ailments.
Lupin said, according to estimates, India has nearly 35 million people living with asthma, including children. While there is no cure for asthma, it is manageable with proper treatment, vigilance, drug adherence, and regular medical checks, thus enabling patients to lead a normal life, the company added.
Rajeev Sibal, President – India Region Formulations, Lupin said, Studies indicate that nearly 90 percent of patients don’t use their inhalers correctly.
This can have multiple implications such as developing uncontrolled symptoms, a higher rate of asthma attacks, or even flare-ups.
Lupin targets to have this platform serve as a pan India integrated campaign to assist healthcare professionals in significantly helping their patients understand correct inhalation technique and better manage their ailment.
The Global pharma major also announced that it has received approval for its Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Truvada® Tablets, 200 mg/300 mg, of Gilead Sciences, Inc.
The product which will be manufactured at Lupin’s facility in Nagpur, India, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is also used for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection
Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (RLD: Truvada®) had estimated annual sales of USD 2.1 billion in the U.S. (IQVIA MAT March 2021
Bayer launches Consumer Health division in India
Global life sciences firm has launched its Consumer Health division in India comprising 10 brands across the categories of allergy, dermatology, nutrition and analgesics.
These brands include Saridon, Supradyn, Becozym C Forte, Benadon, Alaspan, Canesten and Bayer’s Tonic. These products will be manufactured locally in India, Bayer said in a statement.
The Bayer Consumer Health division aims to expand access to everyday health solutions and reach over a 100 million consumers across all communities in India over the next five years.
The division will strengthen Bayer’s presence in India, complementing its existing Crop Science and Pharmaceuticals divisions, and leverage digital opportunities across the entire value chain to scale access to healthcare and personalized self-care solutions, as well as reliable health information.
“Bayer’s Consumer Health division in India aims to make self-care a reality for 1.4 billion Indians so that they can keep pursuing all their dreams without any health hiccups,” Bayer Consumer Health Division, India, Country Head Sandeep Verma said.
To raise consumer health awareness and give further impetus to responsible self-care in the country, Bayer Consumer Health has also launched Self-Care Council.
The company also plans to launch a national self-care knowledge service, a digitally enabled platform to empower consumers with uninterrupted access to reliable and credible information on self-care.
